A director proposes selling 81,056 ImmunityBio (IBRX) shares, including 55,979 from option exercises.
ImmunityBio director Cheryl Cohen has proposed selling 81,056 common shares, valued at approximately $752,199.68, with an anticipated sale date of October 2, 2026. The proposed sale includes 55,979 shares from stock option exercises on the same date and 25,077 shares from restricted stock units acquired on June 6, 2019. This transaction is reported via a Form 144 filing, which outlines the conditions under which restricted or insider-held shares can be publicly resold.
Jefferies upgrades ImmunityBio stock to Strong Buy
Jefferies has upgraded ImmunityBio stock to a Strong Buy rating, leading to an 11.77% price increase on October 2, 2026. Seven analysts have set an average target of USD 14.20, significantly above its current trading price, though analyst ratings are not unanimous. The company reported strong revenue growth in Q2 2026, driven by its lead immunotherapy ANKTIVA, but continues to face profitability challenges with a loss per share of USD 0.22.
ImmunityBio Stock Jumps: What's Going On?
ImmunityBio (IBRX) shares have been steadily rising over the past several months, with its stock chart showing a consistent upward trend despite choppy trading. The stock recently saw a sharp increase from $8.25 to $10.12 in two trading days, though the specific news driving this surge is not yet confirmed. Investors are now watching whether the stock can maintain its position above the $10.12-$10.50 range, as it currently trades near this level, to determine the staying power of this recent move.
IBRX Stock Climbs As Chairman Backs PDS Biotechnology PIPE
ImmunityBio Inc. (IBRX) stock has climbed over 10% after its Executive Chairman, Patrick Soon-Shiong, backed a PIPE financing in PDS Biotechnology and joined its board. While the company states its fundamentals remain unchanged, traders are speculating on future collaborations and the expansion of Soon-Shiong's oncology ecosystem. This move is driving bullish sentiment and technical strength in IBRX, despite the company's significant losses and cash burn.
ImmunityBio Shares Rise as Investors Revisit ANKTIVA Expansion and Revenue Momentum
ImmunityBio shares increased as investors re-evaluated the company's prospects, particularly regarding the expansion of ANKTIVA and potential revenue growth. The article suggests renewed investor confidence in the company's future performance.
ImmunityBio Stock Analysis: Bullish Breakout in October
ImmunityBio stock (IBRX) experienced a significant bullish breakout, closing up 6.91% at $9.44 and touching $10 intraday for the first time since March. Technical analysis indicates a strong bullish alignment across daily and hourly charts, supported by momentum indicators and institutional interest. While a short-term pullback is noted on the 15-minute chart for digestion, the overall evidence favors a continuation of the bullish trend, with key resistance levels at $9.48 and $10.05.
IBRX Stock Holds Gains As Soon‑Shiong Expands Oncology Network
ImmunityBio Inc. (IBRX) stock is trading up after its chairman, Patrick Soon-Shiong, expanded his oncology network by leading PIPE financing into PDS Biotechnology and joining its board. This strategic move, while not immediately changing ImmunityBio's fundamentals, signals a long-term strategy for collaboration within the oncology ecosystem. The stock's steady appreciation and strong intraday trends suggest institutional accumulation and interest from momentum traders.
ImmunityBio Stock Analysis: Bullish Trend Today with Key Resistance
ImmunityBio stock surged over 10% on Wednesday, reaching $9.735, indicating a bullish trend supported by strong EMA alignment and positive momentum indicators. While the daily and hourly charts confirm this bullish outlook, the 15-minute chart suggests a potential short-term pause due to overbought conditions. Key resistance levels are identified at $10.24, with the $9.57–$9.74 pivot zone acting as crucial support.
Immunitybio Inc Stock (IBRX) Moved Up by 11.15% on Sep 30: What Signal Does It Send?
ImmunityBio Inc. (IBRX) stock rose by 11.15% due to strong commercial momentum for its immunotherapy ANKTIVA, positive analyst sentiment, and strategic corporate developments. Wall Street analysts maintain a bullish consensus with an average price target of $12.75. Despite this, the company faces risks including widening net losses, equity dilution, concentrated governance, and regulatory execution risk.
IBRX Stock Grinds Higher As Chairman Expands Oncology Reach
ImmunityBio Inc. (IBRX) stock has been steadily rising, driven by investor optimism following pivotal trial success and strategic moves by its Executive Chairman, Patrick Soon-Shiong. Soon-Shiong is leading a PIPE financing into PDS Biotechnology and joining its board, expanding his oncology ecosystem and potentially fostering future collaborations for ImmunityBio's cancer pipeline. Despite significant financial losses and cash burn, IBRX's strong liquidity and the positive market reaction to these strategic developments are fueling its momentum, making it a "story stock" for active traders.
ImmunityBio Inc Revenue Breakdown – HAN:26CA
ImmunityBio Inc (HAN:26CA) generated 96.46 million EUR in revenue last year, primarily from its Immunotherapies segment. The United States was the largest contributor to this revenue, accounting for 96.22 million EUR. This represents a significant increase from the previous year's figures of 14.24 million EUR for Immunotherapies and 13.73 million EUR from the US.
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for ImmunityBio Inc. (IBRX) stock, showing its current price and daily change. It also includes information on analyst ratings (currently unavailable) and earnings (no information provided). The article is presented within a trading education platform, cautioning readers about the risks and low profitability rates associated with day trading.
Is ImmunityBio (IBRX) A Bargain As Turkey Expansion Fuels Fresh Growth Hopes?
ImmunityBio (IBRX) shares climbed nearly 10% following its founder’s meeting with the Turkish President, signaling expansion into Turkey’s cancer care market. Despite a recent cool-off in momentum, the company's valuation storyline pegs its fair value at $13 per share, significantly above its current trading price of $8.64, driven by ambitious expectations for its cancer and immunology pipeline and global expansion of ANKTIVA. The article explores whether the current price fairly reflects ImmunityBio's story, considering both its growth potential and inherent risks.
ImmunityBio, Inc. (IBRX) Stock Price, News, Quote & History
This article provides a comprehensive overview of ImmunityBio, Inc. (IBRX), a biotechnology company focused on immunotherapies for cancer and infectious diseases. It details the company's stock performance, key financial metrics, earnings trends, analyst ratings, and product pipeline, including its FDA-approved drug Anktiva. The information is current as of September 25, 2026, with financial data up to Q2 FY26.
ImmunityBio Advances Patient-Centric Clinical Trial Design in Bladder Cancer
ImmunityBio, Inc. participated in the World Bladder Cancer Patient Forum 2026 in Hong Kong to advocate for patient-centric clinical trial design in bladder cancer. Anjali Malhotra from ImmunityBio joined a panel to discuss the importance of involving patients in research development. This initiative highlights the company's commitment to advancing bladder cancer care and advocacy globally.
ImmunityBio, Inc. Tokenized Stock (Robinhood) to Euro Price Today | Live IBRX to EUR Converter & Exchange Rate
This article from CryptoRank.io discusses the current lack of a live exchange rate for ImmunityBio, Inc. Tokenized Stock (Robinhood) (IBRX) to Euro (EUR). It notes that no price data is available, likely due to the cryptocurrency not being traded or having very low trading volume. The article also touches on various factors that could affect the token's price once it becomes active.
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
ImmunityBio (IBRX) shares surged by nearly 10% after its founder, Dr. Patrick Soon-Shiong, met with Turkish President Recep Tayyip Erdogan, indicating progress on the company's expansion into Turkey. This development follows the FDA approval of ImmunityBio's immunotherapy drug Anktiva, which has already been accepted in 34 countries and significantly boosted the company's Q2 revenues. Institutional investors are also bullish on IBRX, increasing their combined holdings by over 62% in the last quarter.
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
ImmunityBio Inc. (IBRX) shares jumped 9.94% after its founder, Dr. Patrick Soon-Shiong, met with Turkish President Recep Tayyip Erdogan, sparking optimism about the company's planned expansion into Turkey. This expansion follows the FDA approval and international acceptance of its immunotherapy drug Anktiva in 34 countries. The company also reported strong Q2 revenues, nearly doubling year-over-year, and increased institutional investor conviction.
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
ImmunityBio (IBRX) shares saw a significant jump after founder Patrick Soon-Shiong teased a push into blockchain-based stock trading at Nant, leading to speculation that IBRX shares could become tokenized. This follows the SEC's "Innovation Exemption" creating a pathway for tokenized versions of U.S.-listed securities. Nant is actively building a blockchain-enabled capital-markets platform, which retail traders believe could reduce "phantom shares" and pressure short sellers.
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
ImmunityBio (IBRX) shares saw a surge after founder Patrick Soon-Shiong hinted at Nant's upcoming venture into blockchain-based stock trading, leading to speculation among retail traders that IBRX could become a tokenized stock. This speculation is fueled by the SEC's new "Innovation Exemption" which provides a five-year pathway for trading tokenized U.S.-listed securities. Nant is actively building a comprehensive blockchain trading platform to facilitate this new form of capital market.
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
ImmunityBio (IBRX) shares saw a significant jump after founder Patrick Soon-Shiong teased Nant's upcoming launch of blockchain and tokenized stocks, following the SEC's new "Innovation Exemption." This has led to retail speculation that IBRX shares could be tokenized, with traders discussing the potential impact on short sellers and the efficiency of capital markets. Nant Global Finance is actively building a blockchain-enabled capital-markets platform, integrating various capabilities through acquisitions.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ImmunityBio, Inc. (IBRX) for potential corporate wrongdoing. The firm encourages shareholders who purchased ImmunityBio securities before January 19, 2026, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital.
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
PDS Biotech announced the initial closing of a PIPE financing, raising $11.3 million, led by Nant Capital. The financing aims to fund clinical programs and advance PDS0301 into late-stage development. Additionally, Dr. Patrick Soon-Shiong and James Banaag have been appointed to the company's board of directors.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (IBRX) securities. The investigation focuses on whether ImmunityBio and its officers engaged in corporate wrongdoing. Investors who purchased shares prior to January 19, 2026, are encouraged to contact the firm to assist with the investigation, with no out-of-pocket cost for investors.
IBRX to IDR: ImmunityBio, Inc. • Robinhood Token Price in Indonesian Rupiah
This article provides the current conversion rate of ImmunityBio, Inc. (IBRX) Robinhood Token to Indonesian Rupiah (IDR), showing that 1 IBRX equals Rp140,257. It details how to buy IBRX with IDR, including steps for identifying exchanges, choosing a DEX, acquiring a base cryptocurrency, setting up a crypto wallet, and executing the trade. The article also presents IBRX price statistics, historical data, and various conversion tables.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ImmunityBio, Inc. (IBRX) for alleged corporate wrongdoing, encouraging stockholders who purchased securities before January 19, 2026, and still hold them, to join the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ImmunityBio, Inc. (IBRX) regarding potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact them to learn more and assist with the investigation. The firm operates on a contingency fee basis, meaning no upfront cost for investors.
Does ImmunityBio’s (IBRX) Jim Yong Kim Hire Transform Its Global Access Strategy For Immunotherapies?
ImmunityBio, Inc. has appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman, focusing on global relationships to expand access to its immunotherapy platform. This strategic hire is expected to significantly bolster the company's international rollout capabilities for products like ANKTIVA, especially following its recent marketing authorization in the UAE. While Dr. Kim's expertise strengthens the company's global access strategy, the article notes that investors should still be aware of potential challenges in adoption and reimbursement in new regions.
IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push
ImmunityBio (IBRX) founder Patrick Soon-Shiong revealed plans for a new clinical trial combining Novartis’ Pluvicto with an IL-15-based treatment to enhance targeted radiation therapy for cancer. The announcement comes as IBRX stock experienced a third consecutive day of losses, despite being up 6% for the month. ImmunityBio's flagship drug, Anktiva, an IL-15 based immune activator, is expanding its market reach and boosting sales, although the company continues to report significant net losses.
Does ImmunityBio’s (IBRX) Jim Yong Kim Hire Transform Its Global Access Strategy For Immunotherapies?
ImmunityBio recently appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman to focus on global relationships and access to its immunotherapy platform. This strategic hire leverages Dr. Kim's expertise in global health and development to bolster ImmunityBio's international expansion, especially following the recent marketing authorization for ANKTIVA in the UAE, which expanded the company's footprint to 34 countries. While Dr. Kim's role strengthens international capabilities, the core investment narrative still hinges on ANKTIVA's growth and successful global regulatory approvals and reimbursement.
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
ImmunityBio, Inc. (NASDAQ:IBRX) has received a "Moderate Buy" consensus rating from analysts, with six out of seven brokerages recommending a buy. The average 12-month price target is $14.20, significantly higher than the current share price of $7.72. Despite quarterly earnings missing analyst expectations, the company's revenue exceeded estimates, and institutional investors have been increasing their holdings.
Patrick Soon-Shiong to Thomas Ichim: Thanks for Sharing Important Difference Between Il-2 and Il-15
Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, acknowledged a post by Thomas Ichim, President and Chief Scientific Officer at Immorta Bio, highlighting the critical difference between IL-2 and IL-15 in cancer immunotherapy. Soon-Shiong emphasized that IL-2 stimulates suppressor cells while IL-15 activates killer cells, suggesting that past immunotherapy development may have focused on the wrong cytokine. This interaction underscores the importance of a paper titled "Advances in IL–15–Based Cancer Immunotherapy and Divergent Immunological Effects of IL–2 and IL–15 Signaling via the Shared IL–2Rβγ Receptor."
ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention?
ImmunityBio (IBRX) has garnered renewed attention after appointing Dr. Jim Yong Kim as Vice Chairman, signaling a focus on expanding global partnerships and access to its immunotherapy programs. Despite a significant year-to-date share price increase of 292.08%, the company's valuation narrative suggests it is 39.1% undervalued, with a fair value of $13 per share based on projected global expansion of ANKTIVA. However, the article cautions that this potential is contingent on successful trial outcomes and regulatory approvals.
ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention?
ImmunityBio (IBRX) is gaining attention due to the appointment of Dr. Jim Yong Kim as Vice Chairman, aimed at enhancing global partnerships and access to its immunotherapy programs. The stock has seen significant price increases, with a 292.08% year-to-date return, and a narrative suggests it is 39.1% undervalued with a fair value of $13 per share based on the global expansion of ANKTIVA. Investors are advised to consider both opportunities and risks, such as potential trial failures or regulatory challenges.
147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.
Hussman Strategic Advisors Inc. acquired 147,000 shares of ImmunityBio, Inc. (IBRX) during the second quarter, valued at approximately $1.29 million. Institutional investors now hold 8.58% of the company, while corporate insiders own 66.10%, despite recent insider selling totaling about $3.92 million. ImmunityBio reported a Q2 loss of $0.22 per share but exceeded revenue estimates with $51.24 million, and analysts currently rate the stock as a "Moderate Buy" with an average price target of $14.20.
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)?
ImmunityBio (IBRX) recently appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman to focus on global strategy and international access to its therapies. This move signals ImmunityBio's intent to engage more deeply with governments and public health agencies, influencing how its treatments are introduced and accessed globally. While Dr. Kim's expertise could bolster long-term international growth, the company still faces significant near-term challenges including heavy cash burn and deepening losses despite growing sales.
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)?
ImmunityBio recently appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman to lead global strategy and international access for its immunotherapy platform. This move signals ImmunityBio's intention to engage more deeply with governments and public health agencies worldwide, impacting how its therapies will be introduced and accessed internationally. While this suggests a focus on long-term global expansion, it occurs amidst growing sales but also deepening financial losses, highlighting a tension between ambitious growth and financial strain.
Jim Yong Kim Joins ImmunityBio as Vice Chairman
ImmunityBio has appointed Jim Yong Kim, former President of the World Bank Group, as its Vice Chairman. In this new role, Kim will focus on strengthening the company's international relationships and supporting global partnerships and access initiatives for its immunotherapy platforms, clinical programs, and approved therapies. His extensive background in global health and development finance is expected to aid ImmunityBio's mission to make scientific and medical advancements accessible to those most in need.
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough
ImmunityBio (IBRX) stock saw a jump after executive chairman Patrick Soon-Shiong revealed a three-year expansion plan for the BioShield platform, which includes Anktiva. The company is expanding Anktiva's reach globally, notably into Saudi Arabia and across Europe, following recent regulatory approvals. Soon-Shiong also highlighted the potential of Anktiva's IL-15 mechanism in cancer immunotherapy and outlined plans for a "world bank of natural killer cells" using AI-driven manufacturing.
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus
This article highlights several technology and growth companies, including Archer Aviation (ACHR), ImmunityBio (IBRX), Sphere 3D Corp. (ANY), Graphene Manufacturing Group (GMG), and Socket Mobile (SCKT), which are attracting investor attention due to recent corporate, technology, and strategic developments. Archer Aviation is expanding its position in advanced air mobility, ImmunityBio appointed a new Vice Chairman to its board, Sphere 3D Corp. is repositioning around digital infrastructure and AI, Graphene Manufacturing Group is revitalizing its battery brand, and Socket Mobile announced a strategic partnership for its mobility solutions. These companies represent key investment themes such as eVTOL, biotechnology, AI/HPC infrastructure, advanced batteries, and enterprise mobility.
Jim Yong Kim Joins ImmunityBio as Vice Chairman – ImmunityBio
ImmunityBio announced that Dr. Jim Yong Kim, former President of the World Bank Group, has joined the company as Vice Chairman. He will be part of the newly formed Office of the Executive Chairman and will focus on strengthening ImmunityBio's international and global relationships. His extensive experience in medicine, public health, and development is expected to be crucial in the company's mission to deliver immune activation benefits to patients globally.
ImmunityBio Names Former World Bank President Jim Yong Kim Vice Chairman
ImmunityBio, Inc. (NASDAQ: IBRX) has appointed former World Bank President Dr. Jim Yong Kim as vice chairman to strengthen international partnerships for its immunotherapy programs and approved therapies. Kim will focus on building relationships with governments, health ministries, and multilateral organizations to expand global access to ImmunityBio's treatments. His extensive experience in global health and development finance is expected to be invaluable as the company navigates international commercialization and healthcare systems.
ImmunityBio appoints Jim Yong Kim as vice chairman
ImmunityBio, Inc. (NASDAQ:IBRX) has announced the appointment of Dr. Jim Yong Kim as vice chairman, who will focus on international partnerships and global access initiatives within the newly created Office of the Executive Chairman. Dr. Kim, a former president of the World Bank Group and co-founder of Partners In Health, will leverage his extensive experience in global health to support the company's immunotherapy platform and therapies outside the United States. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong.
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
ImmunityBio, Inc. (NASDAQ: IBRX) has appointed Dr. Jim Yong Kim, former World Bank President, as Vice Chairman to lead international partnerships and global access initiatives. Dr. Kim will work within a newly formed Office of the Executive Chairman, reporting to Dr. Patrick Soon-Shiong, to expand global access to ImmunityBio's immunotherapy platform and approved therapies. His extensive background in global health, development finance, and government relations is expected to accelerate the company's scientific and clinical programs worldwide.
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
ImmunityBio, Inc. has appointed Dr. Jim Yong Kim, former World Bank President and global health leader, as Vice Chairman. In this newly created role within the Office of the Executive Chairman, Dr. Kim will focus on strengthening international relationships, engaging with governments and health ministries, and supporting global access initiatives for ImmunityBio's immunotherapy platform. His extensive experience in medicine, public health, and global finance is expected to be invaluable in advancing the company's scientific programs and expanding access to its therapies worldwide.
Royal Bank of Canada Has $11.40 Million Holdings in ImmunityBio, Inc. $IBRX
Royal Bank of Canada significantly increased its stake in ImmunityBio, Inc. (NASDAQ:IBRX) by 1,731.8% in the first quarter, now holding 1.4 million shares valued at $11.4 million. Despite the company reporting a larger-than-expected quarterly loss of $0.22 per share, institutional ownership remains at 8.58% and analysts have a "Moderate Buy" consensus rating with an average price target of $14.20. Recent insider transactions show sales by two directors, though company insiders still own 66.10% of the stock.
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach
ImmunityBio (IBRX) is under investor scrutiny after receiving marketing authorization in the UAE for ANKTIVA, used for bladder cancer and lung cancer. While the stock has seen significant year-to-date gains, its current valuation reflects rich revenue multiples and ongoing losses. Analysts present mixed views, with some seeing the company as undervalued with a fair value of $13, driven by aggressive growth forecasts, while others point to high sales multiples and remaining risks.
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next
ImmunityBio (IBRX) saw its stock rise by 6.6% following its Q2 2026 results and the expanded UAE marketing authorization for its immunotherapy ANKTIVA, now covering bladder and lung cancer in 34 countries. Despite increased revenue, the company reported wider net losses, highlighting the challenge of balancing commercial expansion with significant ongoing losses. The article emphasizes that while regulatory approvals are positive, the company's investment narrative remains centered on ANKTIVA's ability to evolve into a broader oncology platform amidst continued substantial losses.
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next
ImmunityBio (IBRX) saw its stock rise by 6.6% following its Q2 2026 results, which showed increased revenue but also a wider net loss. The company also secured broad UAE marketing authorization for its immunotherapy ANKTIVA for bladder and lung cancer, expanding its global regulatory footprint to 34 countries. This development highlights the company's growing commercial reach despite significant ongoing losses, and future expectations will hinge on ANKTIVA's broader oncology platform development and further regulatory progress.
ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value
ImmunityBio (IBRX) has shown strong stock performance with a 321.9% gain over three years, driven by recent approvals for ANKTIVA. However, the stock appears overvalued based on its current Price-to-Sales (P/S) ratio of 46.8x, significantly higher than the biotech industry average. While there is optimism around future growth and revenue potential, the current valuation implies high expectations, leaving limited room for disappointment.
